PolyPid agreed a commercialization deal with Azurity Pharmaceuticals for a surgical site infection prevention drug in the U.S. and Canada, with total potential value of more than $320 million. The agreement is a meaningful funding/commercialization step for PolyPid and should improve visibility into future revenue streams.
PolyPid agreed a commercialization deal with Azurity Pharmaceuticals for a surgical site infection prevention drug in the U.S. and Canada, with total potential value of more than $320 million. The agreement is a meaningful funding/commercialization step for PolyPid and should improve visibility into future revenue streams.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
